Global analytical science and device company Trajan Group Holdings (ASX:TRJ) has today announced the signing of a binding share purchase agreement and a real estate purchase agreement to acquire 100 per cent of Chromatography Research Supplies (CRS).
CRS is a leading US-based manufacturer of high-quality analytical consumables based.
Having operated for over 25 years, CRS is a leading manufacturer of electronic and manual crimping tools, gas filters, ferrules, and injection port septa. Its products are used in analytical laboratories and various other industries worldwide and are known for their quality, ease of use and high levels of support.
Trajan said the acquisition is highly complementary to its existing product portfolio in the analytical workflow and consolidates its current market leading position in gas chromatography sample introduction, supporting the quality of flow path connection and sealing functions with two leading product lines – septa and ferrules.
CRS has been a long-term supplier of consumables to Trajan since its acquisition of SGE Analytical in 2013.
In addition, the acquisition extends Trajan’s portfolio via CRS’ other product lines.
Trajan said the acquisition will be completed for a price of US$43.3 million. It said it has identified significant revenue and cost synergies, as well as corporate savings.
Trajan CEO and managing director Stephen Tomisich said, “The acquisition of CRS enhances multiple areas of our business and builds on our previous successful acquisitions to deliver comprehensive and best-in-class products in the analytical workflow.
“Our market leadership in gas chromatography is enhanced with the addition of septa and ferrules components, as well as introducing a broader portfolio of products in other areas of the analytical workflow that build on our automation business.
"As with our previous acquisitions, we have partnered with CRS for many years, understand their business, and know precisely where they fit within Trajan. The acquisition is earnings accretive and able to be rapidly integrated. Importantly, our acquisitions are building on capabilities to achieve our vision of personalised, preventative, data-based healthcare.”